This creates a clinical dilemma: in patients with advanced DR, clinicians must weigh the small but possible risk of worsening retinopathy against the clear renal and cardiovascular benefits that make GLP-1 RAs a valuable therapy [21]. This evidence concerns the gene GCG and retinal disorder.